Clinical outcomes of critical illness polyneuropathy

Pharmacotherapy
Sandra L Kane, Joseph F Dasta

Abstract

It is often difficult to isolate the origin of acute weakness in the critically ill population because of multiple etiologies. Aminoglycosides, corticosteroids, and neuromuscular blockers frequently are implicated as the source of acute weakness. Recently, critical illness polyneuropathy (CIP), a syndrome of unknown etiology, was added to the differential diagnosis. The frequency of CIP is approximately 70% in patients with sepsis. Early studies of CIP, which were mostly retrospective, underestimated its frequency due to the complexity of the diagnosis and unfamiliarity with the syndrome. Prospective studies have explored the causality and clinical outcomes of CIP Clinical outcomes of patients with CIP include difficulty weaning from mechanical ventilation, increased length of stay, prolonged recovery, and an overall mortality rate of 26-71%. The association of CIP with sepsis, multiorgan failure, and drugs is still unclear.

References

May 1, 1986·Journal of Neurology, Neurosurgery, and Psychiatry·C F BoltonW J Sibbald
Feb 1, 1987·Muscle & Nerve·C F Bolton
Nov 1, 1984·Journal of Neurology, Neurosurgery, and Psychiatry·C F BoltonW J Sibbald
Feb 1, 1995·The Journal of Pediatrics·R D ShethJ B Bodensteiner
Oct 1, 1994·Mayo Clinic Proceedings·E F WijdicksD R Gracey
Feb 1, 1994·Clinical Neurology and Neurosurgery·F S Leijten, A W de Weerd
Jun 8, 1996·Lancet·N LatronicoA Candiani
Sep 1, 1996·Intensive Care Medicine·K BerekN J Mutz
Sep 1, 1996·Intensive Care Medicine·F S LeijtenJ E Harink-De Weerd
Oct 1, 1996·Neurología : publicación oficial de la Sociedad Española de Neurología·J M Grau, O Miró
Nov 14, 1997·Anaesthesia and Intensive Care·J L NatesD V Tuxen
Sep 19, 1998·Journal of the Neurological Sciences·U A ZifkoC F Bolton
Oct 3, 1998·Intensive Care Medicine·J H CoakleyC J Hinds
Mar 23, 1999·Muscle & Nerve·C F Bolton, A C Breuer
Feb 25, 2000·European Neurology·M de SèzeM Barat
May 24, 2000·The Netherlands Journal of Medicine·M TepperA J Woittiez
Jan 3, 2001·Muscle & Nerve. Supplement·U A Zifko
Feb 24, 2001·Disability and Rehabilitation·M van der SchaafI J de Groot
Mar 10, 2001·The New England Journal of Medicine·G R BernardUNKNOWN Recombinant human protein C Worldwide Evaluation in Severe Sepsis (PROWESS) study group
Aug 21, 2001·Intensive Care Medicine·J Garnacho-MonteroM R Moyano-Del-Estad
Aug 30, 2001·Neuromuscular Disorders : NMD·T J GellerG R Hayat

❮ Previous
Next ❯

Citations

Nov 3, 2006·Canadian Journal of Anaesthesia = Journal Canadien D'anesthésie·Michael J MurrayCharles F Bolton
Sep 28, 2002·Current Opinion in Neurology·Christian Krarup
Jul 5, 2012·American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists·Jennifer ConferRobert Hayes

❮ Previous
Next ❯

Related Concepts

Related Feeds

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.